Natco Pharma received a US FDA EIR for its Mekaguda API unit after a June inspection with a single VAI observation.

• Inspection occurred from June 9–13, 2025; only one observation was noted, categorized as voluntary action indicated (VAI).
• Regulatory filing confirms receipt of Establishment Inspection Report (EIR), indicating closure of inspection process.
• Natco develops APIs, generics, specialty drugs, and crop protection products from its Hyderabad-based headquarters.